ECElodie Charuel

Elodie Charuel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elodie Charuel has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Designing DECIdE Together: An Interprofessional and Patient-Centered Approach to Develop a Patient Decision Aid for Drugs in Primary Care (DECIsion in hEalth)

    by Elodie Charuel, Thibault Menini, Sarah Chateauneuf, Léa Mathieu, Mélody Mailliez, Céline Deveuve-Murol, Marielle Duchassaing, Sabrina Bedhomme, Philippe Vorilhon, Hélène Vaillant-Roussel

    Background. In primary care, general practitioners (GPs) and community pharmacists (CPs) play pivotal roles in guiding patients’ drug choices. Nonprescription drugs (NPDs), which are dispensed with or without a prescription, represent significant health care costs. NPDs are most often used for symptomatic relief and may be subject to shared decision making. We designed shared DECIsion in hEalth (DECIdE), a patient decision aid for NPDs in primary care, via a 3-step user-centered approach. Design. In the first step, a nominal group composed of potential future users (patients, GPs, and CPs) reached a consensus on the prototype’s specifications. In the second step, GPs, CPs, and their patients tested the prototype in user tests during simulated consultations based on real-life scenarios, and clinical psychologists conducted individual interviews to improve the prototype. In the third step, international experts used the eDELPHI consensus method to validate DECIdE as a shared decision aid. Results. Sixteen participants in the nominal group reached a consensus on 18 specifications. The user tests involved 16 patients and 4 health care professionals across 2 cycles. The prototypes were improved according to an analysis of 20 individual interviews. Fifteen French-speaking experts, searchers, physicians, and pharmacists from 4 countries reached a consensus on 11 of the 13 propositions inspired by the IPDAS criteria and the French HAS criteria in 2 rounds to validate the final prototype of DECIdE. Conclusion . Interprofessional collaboration at each step of development is the main strength of this user-centered design. DECIdE is currently being evaluated for its effects on decisional conflict in GPs’ practices and community pharmacies in a randomized controlled trial. Implications. DECIdE could encourage more rational use of NPDs, particularly in self-medication. Highlights: DECIdE is the first patient decision aid in French for usual drugs in primary care, based on the latest scientific data in line with an evidence-based medicine approach for general practitioners (GPs) and community pharmacists (CPs). DECIdE’s user-centered design includes interprofessional collaboration at each step between searchers, GPs, CPs, and social and clinical psychologists. The original 3 steps of the user-centered design of DECIdE combined user testing with qualitative analysis and 2 successive consensus methods to create and validate the patient decision aid using the nominal group and eDELPHI methods. The free availability of DECIdE on a dedicated Web site will enable GPs and CPs to make widespread use of shared decisions about nonprescription drugs daily.

  • Open Access

    Project Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.

    by Rémy Boussageon, Clara Blanchard, Elodie Charuel, Thibault Menini, Bruno Pereira, Florian Naudet, Behrouz Kassai, François Gueyffier, Michel Cucherat, Hélène Vaillant-Roussel

    Introduction: Evidence-based medicine is the cornerstone of shared-decision making in healthcare today. The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet today, many drugs are prescribed and used without solid evidence of efficacy. Moreover, meta-analyses are the staple to test for drug efficacy and adverse effects, but spins can lead to unconvincing conclusions. In a shared medical decision-making approach, general practitioners need drug assessment to be based on patient-important outcomes. The aim of project Rebuild the Evidence Base (REB) is to bridge the gap between the data needed in clinical practice and the data available from clinical research. Methods and Analysis: The drugs will be assessed on clinical patient important outcomes and for a population. Using the Cochrane tools, we propose to analyse for each population and outcome : 1) a meta-analysis, based on randomised controlled trials (RCTs) with low risk of bias overall ; 2) Confirmatory RCT with low risk of biais overall; 3) Heterogeneity between RCT, and 4) Publication bias assessment. Depending on the results of these analyses, evidence would be rated according to 4 levels: firm evidence, evidence, results to be confirmed (but no evidence) or lack of evidence. Conclusion: Project REB proposes a method for reading and interpreting randomized clinical trials and their meta-analysis to produce quality data for general practitioners to focus on benefit-risk assessment in the interest of patients. If this data does not exist, it could enable clinical research to better its aim.

  • Open Access

    Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis

    by Elodie Charuel, Thibault Menini, Sabrina Bedhomme, Bruno Pereira, Nathalie Piñol‐Domenech, Suzy Bouchant, Rémy Boussageon, Sylvaine Bœuf‐Gibot, Helene Vaillant‐Roussel

    This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart failure, with a focus on important patient outcomes. A systematic review was conducted of double‐blind randomized controlled trials (RCTs) comparing sacubitril/valsartan versus a reference drug, in heart failure patients with reduced (HFrEF) and preserved (HFpEF) ejection fraction, published in French or English. Searches were undertaken of Medline, Cochrane Central, and Embase. The primary outcomes were all‐cause mortality and adverse events. From 2 082 articles analyzed, 5 were included. For all‐cause mortality, the absolute numbers for HFrEF (2 RCTs, 4627 patients) were 16% on sacubitril/valsartan and 18% on enalapril, with a risk ratio (RR) of 0.85 [CI = 0.78, 0.93], and 13% vs 14% in with HFpEF (2 RCTs, 5097 patients), with no statistical difference. Under the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the evidence for HFrEF patients was of moderate quality. For HFrEF patients, an increased risk of symptomatic hypotension and angioedema (low quality of evidence) was shown. There was no statistical difference for the risk of hyperkalemia or worsening renal function. There was a protective RR (0.50 [0.34, 0.75]) for worsening renal function for patients with HFpEF, with a high quality of evidence despite similar absolute numbers (1.4% vs. 2.8%). To keep in mind for shared decision‐making, sacubitril/valsartan reduces all‐cause mortality in HFrEF patients but for HFpEF further data are needed. Take into consideration the small number of studies to date to assess the risks.